Amerikanische Gesellschaft für Hirudotherapie

College ter Beoordeling van Geneesmiddelen — Medicines Evaluation Board

MEB / CBG · Netherlands · europe

Regulatory jurisdiction profileJurisdictional reference
Medical device clearednational regulator

Dutch Medicines Evaluation Board — paired with IGJ (Health and Youth Care Inspectorate) for device oversight; leech-specific regulatory pathway in the Netherlands has not been independently verified by ASH.

Regulatory Profile

Agency type
national regulator
Region
europe
Country
Netherlands
Leech status
medical device cleared
Last ASH review
2026-05-25

Relevant Regulation Codes

  • Wet op de medische hulpmiddelen (Dutch Medical Devices Act)
  • Regulation (EU) 2017/745 (MDR) — direct effect

Prescriber Requirements

  • BIG-registered arts (physician) prescription required under Dutch Individual Health Care Professions Act (Wet BIG)
  • Non-physician practitioner scope for hirudotherapy (e.g., natuurgeneeskundige) has not been independently verified by ASH

Supply Chain & GMP

EU MDR-aligned registration; Dutch-language IFU per consumer-protection law. Cold chain per manufacturer specifications.

Import/Export Rules

Intra-EU free movement for CE-marked devices. Third-country imports through IGJ notification with standard CITES Appendix II paperwork and NVWA (food and consumer product safety authority) veterinary clearance.

Reimbursement Context

Dutch basic health insurance (Zorgverzekeringswet, Zvw) reimburses indications listed in the Zorgverzekering basispakket; specific hirudotherapy coverage status not independently verified by ASH and is likely limited to inpatient flap-salvage settings.

ASH Editorial Notes

Note: MEB / CBG is primarily a medicines regulator; medical-device oversight in the Netherlands is shared with IGJ (Inspectie Gezondheidszorg en Jeugd). The leech-specific regulatory pathway has not been independently verified by ASH and should be reviewed by Dutch counsel before relying on for compliance.

Related Jurisdictions

Diese Website stellt Bildungsinformationen bereit und ist weder eine medizinische Beratung noch eine Diagnose oder Behandlungsempfehlung. Die medizinische Blutegeltherapie ist mit klinisch relevanten Risiken verbunden und sollte ausschließlich von qualifizierten Klinikerinnen und Klinikern unter institutionell genehmigten Protokollen durchgeführt werden. Die FDA-510(k)-Zulassung für medizinische Blutegel ist auf bestimmte Indikationen beschränkt; experimentelle und Off-Label-Diskussionen werden entsprechend gekennzeichnet. Für patientenspezifische Beratung wenden Sie sich an eine qualifizierte Gesundheitsfachkraft.